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ABSTRACT
Introduction: Postnatal vitamin D supplementation
may be associated with a reduction in IgE-mediated
food allergy, lower respiratory tract infections and
improved bone health. Countries in the Northern
hemisphere recommend universal infant vitamin D
supplementation to optimise early vitamin D levels,
despite the absence of large trials proving safety or
efficacy for any disease outcome. With the aim of
determining the clinical and cost-effectiveness of daily
vitamin D supplementation in breastfed infants from
age 6–8 weeks to 12 months of age, we have started a
double-blind, randomised, placebo-controlled trial of
daily 400 IU vitamin D supplementation during the first
year of life, VITALITY.
Methods nd analysis: Infants (n=3012) who are
fully breastfed and not receiving vitamin D
supplementation will be recruited at the time of their
first immunisation, from council-led immunisation
clinics throughout metropolitan Melbourne, Australia.
The primary outcome is challenge-proven food allergy
at 12 months of age. Secondary outcomes are food
sensitisation (positive skin prick test), number of lower
respiratory infections (through hospital linkage),
moderately-severe and persistent eczema (by history
and examination) and vitamin D deficiency (serum
vitamin D <50 nmol/L) at age 12 months. The trial is
underway and the first 130 participants have been
recruited.
Ethics and dissemination: The VITALITY study is
approved by the Royal Children’s Hospital (RCH)
Human Research Ethics Committee (#34168).
Outcomes will be disseminated through
publication and will be presented at scientific
conferences.
Trial registration numbers: ANZCTR12614000334
606 and NCT02112734; pre-results.
INTRODUCTION
Vitamin D is likely to play a role in early
infant immune health, with emerging evi-
dence that early life vitamin D deﬁciency
increases the risk of developing childhood
diseases such as food allergy1 lower respira-
tory infections (LRIs)2 and eczema.3 A
marked shift to vitamin D deﬁciency in early
life in modern populations may be an under-
lying driver of the reported rise in allergic
diseases including food allergy and eczema.
The rise in food allergy in developed coun-
tries is well documented.1 4 5 The increase is
most pronounced in children under 5 years
of age which suggests a causal role for early
life determinants. Recent evidence suggests
that low vitamin D at birth or during infancy
is associated with an increased risk of food
allergy6 and eczema.7 In addition food
allergy and eczema prevalence is higher the
further from the equator a person resides,
lending support to the hypotheses that low
vitamin D (through low ultraviolet (UV)
Strengths and limitations of this study
▪ Allergic disease is on the rise.
▪ Vitamin D deficiency has been associated with
the development of food allergy in infants.
▪ Vitamin D status appears to play an important
role in the adequacy of immune responses to
viral respiratory tract infections.
▪ Large scale trials of postnatal vitamin D for any
disease outcome are lacking.
▪ Vitamin D supplementation could optimise infant
immune health in the first year of life reducing
the risk of allergic disease and respiratory
diseases.
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exposure) may play a role in aberrant immune develop-
ment in early life and increase the risk of developing
food allergy and eczema.3 Food allergy is one of the
earliest manifestations of the immune deviation,8 but
also strongly coassociates with eczema in infancy and
asthma later in life.9
Vitamin D supplementation in the ﬁrst year of life has
also been associated with a reduced risk of LRIs10 and
reduced recovery time in infants with acute bronchio-
litis.11 Since early life wheezy LRIs are also strongly asso-
ciated with longer term respiratory outcomes including
asthma12 understanding the role of vitamin D in the risk
of early life respiratory diseases is also important.
Vitamin D deﬁciency (currently deﬁned as
25OHD3<50 nmol/L) has become more common in
modern communities over time, presumably due to
inadequate sun exposure resulting from indoor activities
and skin cancer concerns.13 Vitamin D deﬁciency is
common in Victoria, Australia and also appears to be
increasing among pregnant women14 and infants.6 In
addition, the prevalence of infant vitamin D deﬁciency
was fourfold higher among fully breastfed infants than
fully formula fed (p<0.001) even at 12 months after
solid food had been introduced.15
Unlike other countries in the Northern Hemisphere,
Australia does not recommend universal vitamin D sup-
plementation. Furthermore as one of the few countries
that does not routinely fortify the food chain supply,
Australia is uniquely placed internationally to assess the
role of vitamin D in early life development.
OBJECTIVES
With the ultimate goal of developing improved public
health guidelines for vitamin D supplementation of
infants, we aim to determine if vitamin D supplementa-
tion in infants from 6 to 8 weeks of age leads to a reduc-
tion in the following during the ﬁrst year of life:
1. Challenge-proven food allergy
2. Lower respiratory infections
3. Food sensitisation
4. Doctor diagnosed eczema
5. Vitamin D deﬁciency
METHODS AND ANALYSIS
Design
VITALITY is a double-blind, randomised, placebo-
controlled trial of vitamin D supplementation during
the ﬁrst year of life. The trial will be conducted and
reported according to CONSORT16 guidelines with the
cost-effectiveness analysis conducted and reported
according to CHEERS guidelines.17
Setting and participants
The trial will be conducted in 6–8 week old breast fed
infants not already receiving vitamin D supplementation.
Infants will be recruited from council run immunisation
sessions within Melbourne, Australia. The study diagram
is shown in ﬁgure 1. We aim to recruit 1506 infants per
arm, 3012 total (see sample size). The study is restricted
to breast fed infants because formula feeding from birth
can be equivalent to vitamin D supplementation as
formula contains approximately 400 IU of vitamin D/L.
The amount of formula that infants consume by age
6 months is based on body weight and amount of solid
food consumed but generally can considered to be
equivalent to the infant receiving <400 IU.
Inclusion and exclusion criteria
Inclusion criteria: Healthy, term, breastfeeding 6–8 week
old infants. Infants of mothers who intend to continue
predominantly breastfeeding until 6 months will be
recruited since formula feeding is a surrogate form of
partial vitamin D supplementation.
Exclusion criteria: Infants with the following will be
excluded: already receiving vitamin D supplementation,
born premature (<37 weeks)/low birth weight
(<2500 g), multiple births, poor health due to a current
or past signiﬁcant disease state or congenital abnormal-
ity or infants on medication that interfere with vitamin
D metabolism. Mothers who receive antenatal vitamin D
supplementation will not be excluded because in our
setting, this has not been shown to be protective against
postnatal infant vitamin D deﬁciency.15
Randomisation
Randomisation will be undertaken using a web-based
randomisation system set up within the trial database
(REDCap). The randomisation schedule will be gener-
ated using permuted blocks of variable lengths by an
independent statistician. To ensure concealment of allo-
cation participants will only be randomised once they
clearly meet inclusion criteria. Participants, their parents
and all members of the study team, aside from the clin-
ical trials pharmacist, will remain blinded to treatment
allocation throughout the trial.
Intervention
Infants will be randomly assigned to receive 400 IU
vitamin D3-Cholecalciferol (1 drop, 0.03 mL) (Baby D
drops) or an identical placebo (1 drop vegetable oil)
daily until 12 months of age. Both active and placebo
interventions will be supplied by the D Drops Company,
Ontario, Canada which currently provides the active
product commercially under the regulation of Health
Canada’s Natural Health Product Directorate.
The current daily dose recommended for infants in
the ﬁrst year of life is 400 IU in all available published
international guidelines; USA18 and UK National Health
Service (NHS) guidelines. A daily dose of 400 IU admi-
nistered from around 4 weeks of age was sufﬁcient to
increase vitamin D levels to ≥50 nmol/L in 98% of
infants by 3 months of age.19
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Compliance
We have developed an iPhone application to remind
study participants to give their infant the study medica-
tion and to monitor dosing compliance. This information
can be emailed from the app to vitality@mcri.edu.au and
incorporated into the REDCapdatabase. An android-
based application is in development. For participants
without smart phones, a paper diary system is available.
These can be sent back via mail or photographed and
emailed. Participants are asked to send their empty
bottles of study medication to the Clinical Trials
Pharmacy for re-weighing to measure compliance with
daily dosing. To date compliance with daily dosing is 90%
based on the number of returned, completed diaries.
Outcomes
Primary
Challenge-proven food allergy at 12 months of age.
Secondary
▸ Number of LRIs by 12 months of age;
▸ Food sensitisation (positive skin prick test) at
12 months of age;
▸ Moderately-severe and persistent eczema at
12 months of age;
▸ Vitamin D deﬁciency at 12 months of age.
Ethics and dissemination
The study has been approved by the Royal Children’s
Hospital (RCH) Human Research Ethics Committee
(#34168) and is registered with the Australia & New
Zealand Clinical Trials Registry (ANZCTR12614000334606)
and U.S. National Institutes of Health (NCT02112734).
Written informed consent will be obtained from all partici-
pants included in the trial. Participants will be informed
that they are not obliged to take part in the study and are
free to withdraw at any time without negative consequences
on their future care. The privacy of participants will be pro-
tected and their names and personal information will be
kept conﬁdential. No serious adverse reactions are antici-
pated in the trial but these will be monitored by the Data
Safety and Monitoring Committee. Outcomes will be disse-
minated through publication according to the SPIRIT state-
ment and will be presented at scientiﬁc conferences.
Data collection
Table 1 summarises timing of measures, described in
more detail below. Web-based questionnaires will be
administered to parents at baseline and when their
Figure 1: Study diagram.
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infant is aged 3, 6, 9 and 12 months. Infants will be
invited in for a clinical assessment, blood sample and
allergy testing at age 12 months at the completion of the
intervention. An optional RCH clinic visit at age
6 months will be offered to participants and will include
an eczema examination and blood draw. Daily diaries
will be used to record compliance with drug dosing,
changes to infant feeding, new allergy symptoms, medi-
cation use and medical visits to inform the economic
evaluation.
Primary outcome
Challenge conﬁrmed food allergy: These will be undertaken
in all participants with a positive skin prick test to food
allergens at age 12 months. Food challenges will follow
Australasian Society of Clinical Immunology and Allergy
(ASCIA) guidelines as used by the RCH Allergy Clinic
and validated within our HealthNuts study in which we
undertook more than 1800 oral food challenges4 6 20 at
age 12 months.
Secondary outcomes
LRIs: The parent questionnaires will capture information
on bronchiolitis, healthcare visits/hospital admissions
and medication use in the past 3 months. We will access
general practitioner (GP) or hospital records to obtain
accurate data on lower respiratory infections.
Food sensitisation: Sensitisation to a panel of allergens
will be assessed in all participants at 12 months of age:
cow’s milk, egg, peanut, cashew, sesame. Skin prick
allergy testing will be performed according to standard
guidelines as per previous HealthNuts protocol.20
Eczema: Eczema history will be assessed by the U.K.
Working Party’s Diagnostic Criteria for Atopic Dermatitis
using parent questionnaire data. Severity of eczema will
be assessed using Scoring of Atopic Dermatitis
(SCORAD)21 at baseline/12 months as follows: Mild—
SCORAD <25, Moderate—SCORAD, 25–50, Severe—
SCORAD ≥50. Persistent eczema will be assessed if age
of onset of eczema was by 9 months and evident at age
12 months.
Vitamin D deﬁciency: Infant 25OHD3 levels and metabo-
lites including the C3-epimer of 25OHD3 will be mea-
sured using liquid chromatography-tandem mass
spectrometry.22 The method will be referenced to the
Joint Commission for Traceability in Laboratory
Medicine’s recommended reference standard to provide
accuracy for the vitamin D result. Participant’s vitamin D
status will be deﬁned by their blood 25OHD3 level, as:
severely deﬁcient <12.5 nmol/L; moderately deﬁcient
12.5–25 nmol/L; mild deﬁciency 26–49 nmol/L; sufﬁ-
cient ≥50 nmol/L; and elevated >220 nmol/L.23
Parent Baseline Questionnaire: To check that potential
environmental and other confounding factors are
balanced between the two randomisation groups, base-
line parent questionnaires will collect data on: parental
smoking, medication use, parental ancestry, ethnicity,
education, employment, occupation, family history of
allergy, use of supplements including vitamin A, D and
cod liver oil, number of siblings; and pet ownership.
Parent Questionnaire (3 monthly): To capture dietary
vitamin D intake and environmental UV radiation
(UVR) exposure, we will ask questions about maternal
vitamin D supplements, infant diet, maternal and infant
sun exposure and sun protective behaviours as in our
previous work,15 for example, number of hours spent in
the sun per day, during summer or winter, weekends
and holidays, will be collected for mother and child.
Cumulative UVR dose will be calculated as the product
of time spent outdoors and ambient UVR during the
period. Composite skin exposure and sun protection
indices will be measured. We have established that com-
posite maternal UVR dose (OR 0.50 (95% CI 0.37 to
0.69) p<0.001) and maternal skin exposure index (OR
0.81 (95% CI 0.66 to 0.98) p=0.03) were associated with
breastfed infant vitamin D status but infant time in the
sun during the ﬁrst year was not.15 Infant feeding
(amount of breastfeeding, formula feeding and type of
Table 1 Summary and timing of measures
Timing months Baseline 3 6 9 12
Primary outcomes
Challenge-confirmed food allergy X
Secondary outcomes
Lower respiratory tract infections (validated questionnaires) X X X X X
Food sensitisation (SPT) X
Eczema
(a) Validated questionnaires (history) X X X X X
(b) SCORAD assessment X X
Vitamin D deficiency–blood collection X X
Parent questionnaires
Baseline measures X
Infant feeding X X X X X
Vitamin D dosing/compliance (daily diary) X X X X
Economic data X X
SCORAD, Scoring of Atopic Dermatitis; SPT, skin prick test.
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formula, introduction of solid foods) will also be
recorded. At 12 months only, infant skin/hair/eye
colour will be assessed using a standardised, validated
chart. We have validated that the charts predict
(p<0.001) skin melanin density by spectrophotometer.24
Blood samples (12 months): Peripheral blood mono-
nuclear cells will be separated from whole blood and
stored in liquid nitrogen, and plasma will be stored and
frozen in our −80°C freezer. These will be retained for
future analysis to evaluate immune function including
regulatory T cell and cytokine assays.
Newborn screening (Guthrie) card: consent will be
obtained at recruitment to access Guthrie cards to
undertake assessment of vitamin D levels at birth.
Economic evaluation
The economic evaluation will take on a societal perspec-
tive, including both costs to the health system and
patient out-of-pocket costs. It will model the potential
cost-effectiveness of routine infant vitamin D supplemen-
tation compared to no supplementation, assuming
Australia-wide implementation. The evaluation will
assess the differential impact of supplementation on
primary trial outcomes at 12 months compared with no
supplementation. Costs associated with the intervention
and use of healthcare services including hospital presen-
tations and admissions, outpatient visits, visits to specia-
lists and other providers (including alternative
providers) and medications will be collected at 6 and
12 months to speciﬁcally capture costs associated with
allergic symptoms that may arise in both groups. We will
supplement this data by linking to the Australian
Pharmaceutical Beneﬁts Scheme (PBS) and the Medical
Beneﬁts Scheme (MBS) to obtain costs of pharmaceuti-
cals and Medicare health service utilisation. This data
will enable us to collect information about specialist
visits, GP visits and medications-related costs for children
with the primary and secondary outcomes identiﬁed in
the study, including LRIs. This will be supplemented by
costing data from the Royal Children’s Hospital for
inpatient and outpatient stays, in addition to the parent
questionnaire from which we will gather out-of-pocket
costs for time off work, caregiver time and travel time to
appointments.
Results will be presented in terms of cost per case of
food allergy averted. A sensitivity analysis will assess the
robustness of results to the uncertainty of model para-
meters. We will model the longer term costs and effects
of primary trial outcomes beyond the horizon of the
trial; drawing from published literature, with the poten-
tial to extend the analysis to secondary outcomes deter-
mined to be clinically important as the trial progresses
and related diseases, including bone health.
Statistical analysis
Outcomes will be compared between the vitamin D and
the placebo groups using an intention-to-treat analysis.
For all outcome measures, the magnitude of
between-group differences will be quantiﬁed by calculat-
ing estimated OR with 95% CI for the corresponding
population OR. As a secondary analysis, the analysis will
be repeated in the ‘per protocol’ (infants breastfed for
at least 6 months and fully compliant with the random-
isation and on the basis of 25OHD3 levels achieved).
Further analyses using multivariable logistic regression
will be undertaken to explore the sensitivity of the esti-
mated ORs to covariate imbalance between the groups
due to potential confounding factors introduced post-
randomisation, such as age of onset of formula feeding.
While the design mitigates very strongly against covariate
imbalance between the trial arms, colleagues have
recently shown that post hoc adjustment of the interven-
tion–outcome association for such imbalances can,
under some circumstances, maintain unbiased estimates
while reducing their SE.25 Linear regression will be used
for non-categorical variables.
Sample size
A ﬁnal sample size of 1205 infants in each group (2410
total), will enable us to identify a 30% reduction in food
allergy with 80% power (based on a two-sided test with
α=0.05). A 30% reduction in the prevalence of food
allergy attributed to vitamin D supplementation repre-
sents a clinically important reduction on a population
level. Assuming 80% follow-up at 12 months of age, we
plan to recruit a total of 3012 participants over 3.5 years
(approximately 79 per month).
Start of the study
The trial started in December 2014, with n=130 partici-
pants as of June 2015. Of those eligible 48%% con-
sented to participate. To date 13% have dropped out, on
average within the ﬁrst 6 weeks (5.9±4.0, weeks, mean
±SD, min 0.4-max 15.4 weeks) after recruitment (main
reasons include: difﬁcult to give daily drops, too busy to
comply with the study procedures). There have been no
reported adverse events. Approximately half approached
have an iPhone and 63% of those have activated use of
the VITALITY iPhone drug compliance app. Table 2
shows demographic information for the ﬁrst 130 partici-
pants to be enrolled.
DATA AND SAFETY MONITORING
An independent Data Safety and Monitoring Committee
(DSMC) consisting of at least one Statistical Society of
Australia Inc (SSAI)-Accredited statistician, one consult-
ant paediatric allergist and one external trials expert will
monitor participant safety including unexpected adverse
events which will be reported to the committee as they
occur. Serious adverse events will be reported to the
Royal Children’s Hospital Human Research Ethics
Committee. We will monitor the current literature
including changes in Australian guidelines for infant
vitamin D dosing and send a quarterly report to the
DSMC who will make decisions regarding any
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requirements for trial discontinuation. We will not be
monitoring serum 25(OH)D for safety reasons nor con-
sidering the association between 25(OH)D and outcome
frequency given that 400 IU has been shown to be safe
in term babies,19 26 preterm infants27 and is the current
recommended dose in the USA, Canada, the UK and
Europe.18
DISCUSSION
The results of the VITALITY trial will determine
whether vitamin D supplementation has a role in opti-
mising infant immune health in the ﬁrst year of life,
reducing the risk of allergic disease and respiratory dis-
eases. Furthermore ﬁndings will provide evidence to
inform guidelines for vitamin D supplementation of
infants. This will be the ﬁrst population-based trial of
postnatal infant vitamin D supplementation sufﬁciently
powered to address the impact on any disease outcome
including allergic disease, LRIs and bone health.
The strengths of VITALITY are that it is a large pre-
ventative, population-based trial thus the results are
more likely to be generalisable. Another strength is that
VITALITY will examine multiple important outcomes
including food allergy and lower respiratory infections.
Furthermore we are uniquely placed internationally to
assess the role of vitamin D in early life development
since Australia does not currently recommend universal
infant vitamin D supplementation and is one of the few
countries where there is no routine fortiﬁcation of the
food chain supply.
A logistic issue for VITALITY is that the trial needs to
be large and thus costly, as the outcomes of interest are
low in prevalence. Restricting the trial to infants with
vitamin D deﬁciency would require a smaller trial,
however it would be unethical to randomise these
infants to placebo thereby not treating with vitamin
D. The use of vitamin D supplements in the placebo
group is another potential issue however we are collect-
ing sufﬁcient data regarding feeding practices, supple-
ment use and sun exposure to account for this.
There are several plausible biological mechanisms for
the role of vitamin D in early infant, immune health.
The vitamin D receptor is widely expressed in the
immune system including T cells. In particular, it pro-
motes the expression of Interleukin-10 (IL-10) secreting
T regulatory cells (crucial for maintaining immune toler-
ance) and potentially plays a key role in the induction of
Table 2 Baseline demographics for first participants
n=130*
Characteristic
Maternal age mean±SD
(minimum–maximum)
33.7±4.6 year (19.4–45.5)
Paternal age mean±SD
(minimum–maximum)
36.3±5.5 years (21.0–50.0)
Baby age mean±SD
(minimum–maximum)
7.4 weeks±1.2 (6.0–11.5)
Maternal education n (%)
Year 12 10 (9.0)
Trade certificate 9 (8.3)
University degree 56 (51.8)
Higher degree (eg, PhD,
masters)
28 (25.9)
Other 5 (4.6)
Paternal education
Year 12 14 (13.0)
Trade certificate 25 (23.1)
University degree 45 (41.7)
Higher degree (eg, PhD,
masters)
22 (20.4)
Other 2 (1.8)
Marital status
Single 1 (1.0)
Married 91 (84.3)
Defacto 14 (12.07)
Separated 1 (1.0)
Other 1 (1.0)
Maternal country of birth
Australia 79 (73.1)
Other country 29 (26.8)
Paternal country of birth
Australia 70 (65.0)
Other country 38 (35.0)
Family history of asthma
No 54 (50.0)
Yes 54 (50.0)
Family history of eczema
No 61 (57.0)
Yes 44 (41.1)
Do not know 2 (1.9)
Family history of food allergy
No 75 (70.0)
Yes 30 (28.1)
Do not know 2 (1.9)
Maternal smoking
No 104 (97.2)
Yes 3 (2.8)
Sex of baby
Female 48 (45.7)
Male 57 (54.3)
Baby country of birth
Australia 105 (100.0)
Feeding some formula
No 64 (64.0)
Yes 36 (36.0)
If feeding some formula, infant age when started, weeks
Mean±SD (minimum–
maximum)
2.5±3.1 (0.0–12.0)
Continued
Table 2 Continued
Characteristic
If feeding some formula, times given since birth, days
Mean±SD (minimum–
maximum)
16.0±18.3 (1.0–71.0)
Withdrawn from study n=19.
*Complete data set for n=108 mothers and n=105 infants.
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tolerance in food-allergic individuals. Vitamin D metabo-
lites also contribute to innate epithelial defences by
stimulating production of antimicrobial proteins (eg,
cathelicidins and defensins).14 Vitamin D status appears
to play an important role in the adequacy of immune
responses to viral lower respiratory infections. It acts by
inducing antimicrobial peptides in epithelial cells, neu-
trophils and macrophages28 and increases transcription
of the innate immune protein (hCAP-18) which is
capable of killing a wide variety of viral and bacterial
pathogens.29 These ﬁndings are supported by the obser-
vation that vitamin D receptor polymorphisms (which
decrease the bioavailability of vitamin D to the cell) are
associated with more severe bronchiolitis30 and that
defective control of vitamin D receptor-mediated cell sig-
nalling predisposes to severe respiratory syncytial virus
bronchiolitis.31
CONCLUSIONS
International enthusiasm for supplemental vitamin D
has outpaced available evidence on its effectiveness32
and in fact argument for routine supplementation is in
equipoise. If found to be both efﬁcacious and cost-
effective, vitamin D infant supplementation would
provide a readily available, low harm intervention that
would optimise infant immune health in the ﬁrst year of
life and signiﬁcantly reduce the population burden of
allergic disease. The VITALITY trial will also enable a
future evaluation of whether postnatal vitamin D supple-
mentation is associated with improved bone health in
later childhood—the historical basis of widespread post-
natal vitamin D supplementation, which remains essen-
tially untested.
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